A clinical trial was conducted evaluating the safety and efficacy of recombinant human-activated protein C (rhAPC; drotrecogin alfa [activated]) in preeclampsia, but further studies are needed [131].APC variants have been designed to have a greater ability to destroy histone H3 with fewer anticoagulant properties [132]. This evidence concerns the gene PROC and preeclampsia.